A Prospective, Multicenter, Non-interventional, Real-world Study to Characterize Changes in Molecular Markers After Three Weeks of Targeted Therapy With Oxitinib in EGFRm NSCLC

Inclusion Criteria:

1. ≥18 years old male or female

2. Stage IV metastatic or recurrent non-squamous NSCLC that is newly diagnosed,histologically proven and not suitable for radical surgery or radiotherapy (AJCCV8);

3. Without prior systemic antitumor therapy including EGFR-TKI or immunotherapy;

4. EGFR positive in blood or tissue tested in local laboratory;

5. Sufficient blood samples can be provided for molecular detection;

6. Signed informed consent forms are available.

Exclusion Criteria:

1. Patients were unable to collect plasma samples at baseline;

2. The EGFR mutant status of the patient's blood specimen at baseline has not beenverified by the central laboratory;

3. The patient refused subsequent treatment with oxitinib; 4）The investigatordetermines that may affect the conduct of the clinical study and the judgement ofthe study results.